Michigan is currently home to 2241 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Use of Stratafix Symmetricâ„¢ to Prevent Incisional Hernia in Gastrointestinal and Abdominal Surgery
Recruiting
Comparing the use of Stratafix Symmetricâ„¢ sutures to standard laparotomy closure sutures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: West Michigan Cancer Center, Kalamazoo, Michigan
Conditions: C.Surgical Procedure; Disruption of Wound, Suture
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Recruiting
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: University of Michigan- Kellogg Eye Center, Ann Arbor, Michigan
Conditions: Atopic Keratoconjunctivitis
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
Recruiting
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
01/26/2024
Locations: Ascension St. John Hospital, Detroit, Michigan
Conditions: Rectal Cancer
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Clinical Research Institute of Michigan, Chesterfield, Michigan
Conditions: NASH - Nonalcoholic Steatohepatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Auburn Hills, Michigan
Conditions: Atopic Dermatitis
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Lung Cancer
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Recruiting
At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone. This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.
Gender:
ALL
Ages:
Between 16 years and 50 years
Trial Updated:
01/02/2024
Locations: William Beaumont Hospital, Royal Oak, Michigan
Conditions: Hip Dysplasia
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: CS Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Low-grade Glioma, Advanced Solid Tumor
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Recruiting
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
Conditions: Choroidal Melanoma, Indeterminate Lesions of Eye
Study of ON 123300 in Patients With Advanced Cancer
Recruiting
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumors, Adult